Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells
Biomolecules · 2025
DOI: 10.3390/biom15010055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Sima Kianpour Rad und 11 weiteren Autor:innen. Beteiligte Einrichtung: Solid Tumour Group, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Central Adelaide Local Health Network, Wo…. Hauptthemen laut MEDLINE: Doxorubicin, Triple Negative Breast Neoplasms, Saponins, Triterpenes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Hospital Research Foundation Group, Pre-Clinical Project Grant, The Hospital Research Foundation Group through the Margaret Elcombe Research Fellowship and Pre-Clinical Project.
Abstract (Originalsprache)
Background
Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and high resistance to chemotherapy. Doxorubicin is commonly used, but its efficacy is limited by variable sensitivity and resistance. Bacopaside II, a saponin compound, has shown anti-cancer potential. This study evaluates the effects of doxorubicin and bacopaside II, both individually and in combination, across TNBC subtypes to explore mechanisms of resistance and enhanced drug efficacy.
Methods
The growth-inhibitory effects of doxorubicin and bacopaside II were assessed in four TNBC cell lines. IC50 values were determined using dose–response assays, and doxorubicin accumulation was measured via spectral flow cytometry. ATP-binding cassette (ABC) transporter expression (ABCB1, ABCC1, ABCC3, and ABCG2) was analyzed for correlations with drug sensitivity. In silico docking assessed the binding affinity of bacopaside II to ABC transporters. A 3D culture model simulated drug-resistant TNBC, and combination effects were evaluated with live-cell imaging.
Results
Doxorubicin sensitivity varied across TNBC molecular subtypes, correlating to intracellular accumulation. Bacopaside II inhibited growth across subtypes, inducing apoptosis in sensitive cells and necrosis in resistant cells. Bacopaside II increased doxorubicin accumulation, independent of P-glycoprotein (ABCB1), possibly through interactions with other ABC transporters. In drug-resistant 3D cultures, bacopaside II maintained efficacy and enhanced doxorubicin accumulation, counteracting ABC transporter-mediated resistance. The doxorubicin and bacopaside II combination showed synergistic growth inhibition.
Conclusions
Bacopaside II enhances doxorubicin efficacy in TNBC by increasing drug accumulation and overcoming ABC transporter-mediated resistance, suggesting its potential as an adjuvant in TNBC treatment. These findings support further investigation of bacopaside II, particularly for resistant TNBC subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Solid Tumour Group, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Central Adelaide Local Health Network, Woodville South, Adelaide, SA 5011, Australia.
- Adelaide Medical School, The University of Adelaide, Adelaide, SA 5005, Australia.
- Department of Surgery-Otolaryngology Head and Neck Surgery, The University of Adelaide and the Basil Hetzel Institute for Translational Health Research, Central Adelaide Local Health Network, Adelaide, SA 5000, Australi…
- Medical Oncology, The Queen Elizabeth Hospital, Central Adelaide Local Health Network, Woodville South, Adelaide, SA 5011, Australia.
- Robinson Research Institute, The University of Adelaide, Adelaide, SA 5005, Australia.
- Discipline of Surgery, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Central Adelaide Local Health Network, Woodville South, Adelaide, SA 5011, Australia.
ORCID-Profile: Sima Kianpour Rad, Kenny K L Yeo, Runhao Li, Saifei Liu, Saeed Nourmohammadi, Yoko Tomita, Wendy V Ingman, Eric Smith
Förderung
- The Hospital Research Foundation Group
- Pre-Clinical Project Grant
- The Hospital Research Foundation Group through the Margaret Elcombe Research Fellowship and Pre-Clinical Project
- University of Adelaide Research Scholarships
Zitieren
APA
Rad, S. K., Yeo, K. K. L., Li, R., Wu, F., Liu, S., Nourmohammadi, S., Murphy, W. M., Tomita, Y., Price, T. J., Ingman, W. V., Townsend, A. R., & Smith, E. (2025). Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells. Biomolecules. https://doi.org/10.3390/biom15010055
Vancouver
Rad SK, Yeo KKL, Li R, Wu F, Liu S, Nourmohammadi S, et al. Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells. Biomolecules. 2025. doi:10.3390/biom15010055
BibTeX
@article{Rad2025,
author = {Rad, Sima Kianpour and Yeo, Kenny K L and Li, Runhao and Wu, Fangmeinuo and Liu, Saifei and Nourmohammadi, Saeed and Murphy, William M and Tomita, Yoko and Price, Timothy J and Ingman, Wendy V and Townsend, Amanda R and Smith, Eric},
title = {Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15010055}
}
EUVIMED